bioAffinity Technologies, Inc. announced on May 28, 2025, that the U.S. Patent and Trademark Office (USPTO) has issued a new patent, No. 12,305,171, titled 'Compositions and Methods for Treating Cancer.' This patent covers a novel composition and method for selectively killing cancer cells by targeting the CD320 and LRP2 receptors on the cell membrane.
The patent provides for the use of this therapeutic approach with various cancer types, including lung, breast, prostate, brain, and skin cancers. In vitro studies demonstrated that the dual suppression of these proteins using small interfering RNAs (siRNAs) is selectively cytotoxic to human cancer cells while sparing normal cells.
This patent significantly expands bioAffinity Technologies' intellectual property portfolio into the therapeutic space, complementing its diagnostic platform. The company has initiated research towards developing a topical treatment for cutaneous malignancies and neoplasms of the skin, marking a potential new path to precision treatment across multiple cancer types.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.